Zimmer Biomet Restructures Leadership to Enhance Commercial Transformation Across the Americas
In a significant move towards accelerating its commercial transformation, Zimmer Biomet Holdings, Inc., recognized as a global leader in medical technology, has taken essential steps to refine its leadership structure across the Americas. The recent appointments of Gary Campbell, Brian Hatcher, and Bradley Kessler mark a pivotal shift aimed at fortifying the company's go-to-market strategies and reinforcing its market position.
Effective October 1, 2026, Gary Campbell will step into the role of President for the Americas. In this capacity, he will lead the firm's commercial strategy and execution across the United States, Canada, and Latin America. Prior to this promotion, Campbell was serving as the vice president and general manager for Orthopedics in North America, a role in which he has significantly contributed since joining Zimmer Biomet in 2019. His track record includes various leadership positions that exhibit his depth of expertise in commercial operations, critical for driving growth in the competitive medical technology landscape. With a degree from Texas State University, he is poised to enhance productivity and foster further growth in the region.
Joining Campbell is Brian Hatcher, newly promoted to President of Recon, S.E.T., CMFT, Neuro, and Biosurgery. Hatcher's extensive experience, spanning 16 years at Zimmer Biomet and involving roles in research, marketing, and global leadership, uniquely qualifies him to direct the global portfolio strategy for many of the company’s key business areas, including the expansion into higher growth markets. His educational credentials, featuring a bachelor's in chemistry and a Ph.D. in biomedical engineering from the University of Florida, complement his tenure in the medical technology field, including previous roles at OrbusNeich and Medtronic.
Bradley Kessler has also earned a new title as President for the Americas, focusing on Robotics, Technology, and Data. Kessler will spearhead the commercial strategy and growth initiatives within Zimmer Biomet’s extensive portfolio of robotics and digital solutions in the Americas. His leadership is expected to play a crucial role ahead of the anticipated launch of the Monogram, a next-generation orthopedic robot, set to transform practices in orthopedic procedures in 2027. Kessler's background includes over two decades of experience in orthopedics, having joined Zimmer Biomet in 2015 after a successful tenure in sales with Stryker. He holds a bachelor’s degree from Texas A&M University and an Executive MBA from Southern Methodist University, highlighting his business acumen as essential for driving technological innovation in the sector.
These promotions are indicative of Zimmer Biomet’s commitment to ensuring that the right talent is placed in pivotal roles at the right times, fundamentally supporting their strategic imperative focused on People and Culture. Ivan Tornos, Chairman, President, and CEO of Zimmer Biomet, emphasized that these well-deserved promotions are critical for expediting the company’s transformation efforts and sharpening its commercial priorities.
As part of this strategic redesign, Kevin Thornal, the outgoing Group President for Global Businesses and the Americas, is set to conclude his tenure with Zimmer Biomet on September 30, 2026. Tornos expressed gratitude for Thornal's leadership, acknowledging his contributions and wishing him well in his future endeavors.
Looking ahead, Zimmer Biomet has reiterated its financial outlook for the year 2026, reflecting confidence in its strategic direction and the anticipated impact of these leadership changes on its operational effectiveness.
With a legacy spanning over 90 years, Zimmer Biomet continues to stand at the forefront of the medical technology industry, committed to enhancing patient care through innovative product offerings and a holistic approach that integrates advanced technologies, data analytics, and artificial intelligence. As the company evolves, it remains focused on delivering high-quality solutions, thereby sustaining its reputation as a trusted leader within the healthcare arena. For more insights into Zimmer Biomet’s initiatives and product offerings, interested parties are encouraged to visit their website or follow Zimmer Biomet on their official social media platforms.
Effective October 1, 2026, Gary Campbell will step into the role of President for the Americas. In this capacity, he will lead the firm's commercial strategy and execution across the United States, Canada, and Latin America. Prior to this promotion, Campbell was serving as the vice president and general manager for Orthopedics in North America, a role in which he has significantly contributed since joining Zimmer Biomet in 2019. His track record includes various leadership positions that exhibit his depth of expertise in commercial operations, critical for driving growth in the competitive medical technology landscape. With a degree from Texas State University, he is poised to enhance productivity and foster further growth in the region.
Joining Campbell is Brian Hatcher, newly promoted to President of Recon, S.E.T., CMFT, Neuro, and Biosurgery. Hatcher's extensive experience, spanning 16 years at Zimmer Biomet and involving roles in research, marketing, and global leadership, uniquely qualifies him to direct the global portfolio strategy for many of the company’s key business areas, including the expansion into higher growth markets. His educational credentials, featuring a bachelor's in chemistry and a Ph.D. in biomedical engineering from the University of Florida, complement his tenure in the medical technology field, including previous roles at OrbusNeich and Medtronic.
Bradley Kessler has also earned a new title as President for the Americas, focusing on Robotics, Technology, and Data. Kessler will spearhead the commercial strategy and growth initiatives within Zimmer Biomet’s extensive portfolio of robotics and digital solutions in the Americas. His leadership is expected to play a crucial role ahead of the anticipated launch of the Monogram, a next-generation orthopedic robot, set to transform practices in orthopedic procedures in 2027. Kessler's background includes over two decades of experience in orthopedics, having joined Zimmer Biomet in 2015 after a successful tenure in sales with Stryker. He holds a bachelor’s degree from Texas A&M University and an Executive MBA from Southern Methodist University, highlighting his business acumen as essential for driving technological innovation in the sector.
These promotions are indicative of Zimmer Biomet’s commitment to ensuring that the right talent is placed in pivotal roles at the right times, fundamentally supporting their strategic imperative focused on People and Culture. Ivan Tornos, Chairman, President, and CEO of Zimmer Biomet, emphasized that these well-deserved promotions are critical for expediting the company’s transformation efforts and sharpening its commercial priorities.
As part of this strategic redesign, Kevin Thornal, the outgoing Group President for Global Businesses and the Americas, is set to conclude his tenure with Zimmer Biomet on September 30, 2026. Tornos expressed gratitude for Thornal's leadership, acknowledging his contributions and wishing him well in his future endeavors.
Looking ahead, Zimmer Biomet has reiterated its financial outlook for the year 2026, reflecting confidence in its strategic direction and the anticipated impact of these leadership changes on its operational effectiveness.
With a legacy spanning over 90 years, Zimmer Biomet continues to stand at the forefront of the medical technology industry, committed to enhancing patient care through innovative product offerings and a holistic approach that integrates advanced technologies, data analytics, and artificial intelligence. As the company evolves, it remains focused on delivering high-quality solutions, thereby sustaining its reputation as a trusted leader within the healthcare arena. For more insights into Zimmer Biomet’s initiatives and product offerings, interested parties are encouraged to visit their website or follow Zimmer Biomet on their official social media platforms.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.